U.S. markets open in 3 hours 51 minutes

Avid Bioservices, Inc. (CDMO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
22.07+0.04 (+0.18%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close22.03
Bid17.00 x 800
Ask40.00 x 1200
Day's Range21.24 - 22.32
52 Week Range6.99 - 28.36
Avg. Volume565,115
Market Cap1.354B
Beta (5Y Monthly)2.20
PE Ratio (TTM)206.26
EPS (TTM)0.11
Earnings DateNov 30, 2021 - Dec 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-41% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avid Bioservices, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
  • Zacks

    Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

    Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • Motley Fool

    Avid Bioservices, inc (CDMO) Q1 2021 Earnings Call Transcript

    On today's call, we have Nick Green, President and CEO; and Dan Hart, Chief Financial Officer. Today, we'll be providing an overview of Avid Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31, 2021.

  • GlobeNewswire

    Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments

    -- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter with a Backlog of $110 Million -- -- Phase 1 and Phase 2 Expansion Efforts Advancing as Planned -- TUSTIN, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by prov